Dark Day At Idera As Tilsotolimod Fails To ILLUMINATE In Melanoma Study
Prospects Look Bleak
Executive Summary
The company's TLR-9 agonist has shown little to no benefit over BMS's Yervoy in patients with anti-PD-1 refractory advanced melanoma in a Phase III trial and Idera's stock has nosedived.